Subscribe To
APGE / U.S. IPO Weekly Recap: July IPO Market Kicks Off With Sizable Biotechs
APGE News
By Seeking Alpha
August 22, 2023
Apogee Therapeutics: Potential To Target Autoimmune Disorders With Less Frequent Dosing
Review of Apogee Therapeutics' safety and pharmacokinetic data from phase 1 study using APG777 in healthy volunteers expected in mid-2024. Pending pos more_horizontal
By Seeking Alpha
July 15, 2023
U.S. IPO Weekly Recap: July IPO Market Kicks Off With Sizable Biotechs
Following the Independence Day lull, the July IPO market warmed up with two sizable biotechs, joined by two blank check companies. Surf Air Mobility d more_horizontal
By Proactive Investors
July 11, 2023
Apogee Therapeutics to raise up to $263.1M in IPO
Apogee Therapeutics Inc will offer 15.625 million of its common shares in an initial public offering (IPO) that is expected to be priced between $15 a more_horizontal
By Seeking Alpha
July 10, 2023
IPO Update: Apogee Therapeutics Proposes Terms For $250 Million IPO
Apogee Therapeutics, Inc. has filed proposed terms for a $250 million IPO. The firm is developing drug treatment candidates for atopic dermatitis, COP more_horizontal
By Market Watch
July 10, 2023
Apogee Therapeutics sets IPO terms, to be valued at up to $774.5 mln
Apogee Therapeutics Inc. APGE, has set terms for its initial public offering, as the Massachusetts-based biotechnology company developing treatments f more_horizontal